[ad_1]
Yantai, China, December 3, 2021 /PRNewswire/ – RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, announced today that its two innovative drugs, a dual-targeting TACI-Fc fusion protein Telitacicept (RC18), are used for Treatment of systemic lupus erythematosus (SLE) and the new antibody-drug conjugate (ADC) Disitamab Vedotin (RC48) for the treatment of locally advanced or metastatic gastric cancer have been officially included in this year’s National Medical Insurance List (NRDL).
SLE is one of the diseases with the highest mortality and disability rate in autoimmune rheumatism. According to data from Frost & Sullivan, approximately 7.8 million patients will be diagnosed with SLE by 2020, and it is expected to reach 8.6 million by 2030. There is a large unmet medical need for more effective and better tolerated therapies for the treatment of SLE. Telitacicept is a first-class fusion protein product that can simultaneously inhibit the combination of two cytokines: proliferation-inducing ligand (APRIL) and recombinant B lymphocyte stimulator (BLyS), which has a higher efficacy in the treatment of SLE.
“SLE not only seriously affects the health of patients, but also brings many difficulties to their lives. Telitacicept has brought new changes to the current SLE treatment. China, To maintain a low disease recurrence rate and reduce the patient’s use of glucocorticoids,” said the professor Zhao Yan, Director of Rheumatology Branch of Chinese Medical Association, Chief Physician of Rheumatology Department of Peking Union Medical College Hospital.
Disitamab Vedotin is China’s The first domestic antibody-drug conjugate, suitable for locally advanced or metastatic gastric cancer expressing HER2. According to Frost & Sullivan’s data, gastric cancer is one of the leading causes of cancer deaths worldwide. Nearly 1 million people are diagnosed each year, and more than 700,000 patients die from the disease.
“Gastric cancer has the characteristics of high morbidity and mortality, low early diagnosis rate, and poor prognosis. During the drug development process, we were pleasantly surprised to find…
The full story can be found on Benzinga.com
[ad_2]
Source link
